Published in J Thromb Haemost on November 01, 2010
Fifty per cent of patients with pulmonary embolism can be treated as outpatients. J Thromb Haemost (2010) 1.59
Impact of relative contraindications to home management in emergency department patients with low-risk pulmonary embolism. Ann Am Thorac Soc (2015) 1.46
Validation of the multivariable In-hospital Mortality for PulmonAry embolism using Claims daTa (IMPACT) prediction rule within an all-payer inpatient administrative claims database. BMJ Open (2015) 1.00
Timing of discharge follow-up for acute pulmonary embolism: retrospective cohort study. West J Emerg Med (2015) 0.79
National trends in emergency room diagnosis of pulmonary embolism, 2001-2010: a cross-sectional study. Respir Res (2015) 0.79
Developing a complex intervention for the outpatient management of incidentally diagnosed pulmonary embolism in cancer patients. BMC Health Serv Res (2013) 0.77
Discharge or admit? Emergency department management of incidental pulmonary embolism in patients with cancer: a retrospective study. Int J Emerg Med (2017) 0.75
Managing pulmonary embolism using prognostic models: future concepts for primary care. CMAJ (2011) 0.75
New prospective for the management of low-risk pulmonary embolism: prognostic assessment, early discharge, and single-drug therapy with new oral anticoagulants. Scientifica (Cairo) (2012) 0.75
Empirical evidence of design-related bias in studies of diagnostic tests. JAMA (1999) 12.96
The long-term clinical course of acute deep venous thrombosis. Ann Intern Med (1996) 6.87
Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med (1992) 5.48
A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med (1999) 5.14
Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost (2000) 4.81
Excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and d-dimer. Ann Intern Med (2001) 4.19
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med (1996) 4.10
Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med (2003) 3.94
Is thrombophilia associated with placenta-mediated pregnancy complications? A prospective cohort study. J Thromb Haemost (2014) 3.90
Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med (1996) 3.42
Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet (1999) 2.77
Is it useful to also image the asymptomatic leg in patients with suspected deep vein thrombosis? J Thromb Haemost (2015) 2.62
Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH. J Thromb Haemost (2013) 2.51
Evidence for two components of delayed rectifier K+ current in human ventricular myocytes. Circ Res (1996) 2.50
Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison. Lancet (2000) 2.49
Increased incidence of acute ascending aortic dissection with off-pump aortocoronary bypass surgery? Ann Thorac Surg (2001) 2.47
Subsegmental pulmonary embolism diagnosed by computed tomography: incidence and clinical implications. A systematic review and meta-analysis of the management outcome studies. J Thromb Haemost (2010) 2.43
Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol (2000) 2.35
Trial of vitamin A supplementation in very low birth weight infants at risk for bronchopulmonary dysplasia. J Pediatr (1992) 2.33
Intermittent antegrade warm versus cold blood cardioplegia: a prospective, randomized study. Ann Thorac Surg (1994) 2.30
Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost (2004) 2.28
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost (2013) 2.24
Non-pharmaceutical measures for prevention of post-thrombotic syndrome. Cochrane Database Syst Rev (2004) 2.16
High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost (2000) 2.15
Plasma levels of matrix metalloproteinase-9: a possible diagnostic marker of successful endovascular aneurysm repair. Eur J Vasc Endovasc Surg (2011) 2.14
D-dimer testing is useful to exclude deep vein thrombosis in elderly outpatients. J Thromb Haemost (2008) 2.08
Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation (2004) 2.05
Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study. J Thromb Haemost (2014) 2.03
Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med (1999) 2.00
The risk of venous thromboembolism in renal cell carcinoma patients with residual tumor thrombus. J Thromb Haemost (2014) 1.99
Increased risk of preoperative venous thromboembolism in patients with renal cell carcinoma and tumor thrombus. J Thromb Haemost (2014) 1.98
Deep-vein thrombosis. Lancet (1999) 1.98
Triage of patients for short term observation after elective coronary angioplasty. Heart (2000) 1.97
Transmural heterogeneity of action potentials and Ito1 in myocytes isolated from the human right ventricle. Am J Physiol (1998) 1.92
Tumour necrosis factor (TNF alpha) in leishmaniasis. I. TNF alpha mediates host protection against cutaneous leishmaniasis. Immunology (1990) 1.91
Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev (2004) 1.84
Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med (1999) 1.81
Porcine versus pericardial bioprostheses: a comparison of late results in 1,593 patients. Ann Thorac Surg (1989) 1.76
The risk of recurrent venous thromboembolism in patients with an Arg506-->Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med (1997) 1.75
Comparison of a clinical probability estimate and two clinical models in patients with suspected pulmonary embolism. ANTELOPE-Study Group. Thromb Haemost (2000) 1.73
A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism. Ann Intern Med (2001) 1.72
Diagnosis of arterial disease of the lower extremities with duplex ultrasonography. Br J Surg (1996) 1.68
Decision analysis for cancer screening in idiopathic venous thromboembolism. J Thromb Haemost (2005) 1.65
Screening for occult cancer in patients with acute deep vein thrombosis or pulmonary embolism. J Thromb Haemost (2004) 1.63
A simple classification of the risk in cardiac surgery: the first decade. Can J Anaesth (1993) 1.62
Is the prevalence of the factor V Leiden mutation in patients with pulmonary embolism and deep vein thrombosis really different? Thromb Haemost (1999) 1.60
A randomised clinical trial comparing minimally invasive surgery to conventional approach for endoprosthesis in elderly patients with hip fractures. Injury (2009) 1.58
Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med (1997) 1.57
Prevalence of the JAK2 V617F mutation is low among unselected patients with a first episode of unprovoked venous thromboembolism. J Thromb Haemost (2007) 1.57
Bleeding classification in clinical trials: observer variability and clinical relevance. Thromb Haemost (1997) 1.56
Differential induction of nitric oxide synthase in various organs of the mouse during endotoxaemia: role of TNF-alpha and IL-1-beta. Immunology (1994) 1.55
Improved outcome at 28 days of age for very low birth weight infants treated with a single dose of a synthetic surfactant. J Pediatr (1990) 1.55
Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. The Columbus Investigators. N Engl J Med (1997) 1.54
Right ventricular rupture. A complication of postoperative mediastinitis. J Thorac Cardiovasc Surg (1993) 1.52
Is a good perioperative echocardiographic result predictive of durability in ischemic mitral valve repair? J Thorac Cardiovasc Surg (2006) 1.51
Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost (2006) 1.51
Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost (2000) 1.49
Accuracy of single-detector spiral CT in the diagnosis of pulmonary embolism: a prospective multicenter cohort study of consecutive patients with abnormal perfusion scintigraphy. J Thromb Haemost (2005) 1.46
Outcome of the subsequent pregnancy after a first loss in women with the factor V Leiden or prothrombin 20210A mutations. J Thromb Haemost (2007) 1.44
Once versus twice daily LMWH for the initial treatment of venous thromboembolism. Cochrane Database Syst Rev (2005) 1.43
Microcirculatory investigations to determine the effect of spinal cord stimulation for critical leg ischemia: the Dutch multicenter randomized controlled trial. J Vasc Surg (1999) 1.43
A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost (2000) 1.43
Transmembrane ICa contributes to rate-dependent changes of action potentials in human ventricular myocytes. Am J Physiol (1999) 1.42
Residual vein obstruction as a predictor for recurrent thromboembolic events after a first unprovoked episode: data from the REVERSE cohort study. J Thromb Haemost (2011) 1.42
Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med (1995) 1.41
Contribution of age and intimal lesion morphology to coronary artery wall mechanics in coronary artery disease. Clin Sci (Lond) (1995) 1.41
EVAR suitability is not a predictor for early and midterm mortality after open ruptured AAA repair. Eur J Vasc Endovasc Surg (2011) 1.41
2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group. Ann Oncol (2009) 1.41
Duration of oral anticoagulant treatment in patients with venous thromboembolism and a deficiency of antithrombin, protein C or protein S--a decision analysis. Thromb Haemost (2000) 1.40
[Deep venous thrombosis: does recently improved knowledge lead to a real advance in the direction patient care?]. Ned Tijdschr Geneeskd (1996) 1.39
Prevention of venous thromboembolism in hospitalized medical cancer patients: guidance from the SSC of the ISTH. J Thromb Haemost (2014) 1.39
Risk factors of arterial cardiovascular complications in patients with prior venous thromboembolism. Neth J Med (2011) 1.38
Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost (2008) 1.33
Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives. Thromb Haemost (2000) 1.32
Excessive gestational weight gain predicts large for gestational age neonates independent of maternal body mass index. J Matern Fetal Neonatal Med (2011) 1.31
Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication. Cochrane Database Syst Rev (2006) 1.31
Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost (1999) 1.31
Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology (1996) 1.29
Parathyroid imaging with technetium-99m-sestamibi: preoperative localization and tissue uptake studies. J Nucl Med (1992) 1.28
Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis. J Thromb Haemost (2006) 1.27
Association between antipsychotic drugs, antidepressant drugs and venous thromboembolism: results from the EDITH case-control study. Fundam Clin Pharmacol (2007) 1.27
Management studies using a combination of D-dimer test result and clinical probability to rule out venous thromboembolism: a systematic review. J Thromb Haemost (2005) 1.26
Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Intern Med (2000) 1.24
Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost (1999) 1.23
Lipoprotein(a) concentrations in women with a history of severe preeclampsia--a case control study. Thromb Haemost (1999) 1.23
Physician communication with children and parents. Pediatrics (1982) 1.23
International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost (2013) 1.21
Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost (1999) 1.19
Accuracy of ultrasound for the diagnosis of deep venous thrombosis in asymptomatic patients after orthopedic surgery. A meta-analysis. Ann Intern Med (1995) 1.19
Atrial tissue Doppler imaging for prediction of new-onset atrial fibrillation. Heart (2008) 1.17
Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. Mol Psychiatry (2004) 1.16
Vitamin K epoxide reductase genetic polymorphism is associated with venous thromboembolism: results from the EDITH Study. J Thromb Haemost (2007) 1.16
Low molecular weight heparin versus unfractionated heparin in the initial treatment of venous thromboembolism. Curr Opin Pulm Med (1998) 1.16
Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost (2009) 1.15
Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. J Thromb Haemost (2004) 1.14